PDL Biopharma discloses hostile bid to acquire Neos for $10.25/share; proposal later terminated
PDL BioPharma Inc. made public its launch of a hostile bid to acquire Nasdaq-traded Neos Therapeutics Inc. (modified-release oral drug delivery platform) for $10.25 in cash per share (a 32% premium to the previous 10-day closing average to the October announcement date).
- Generic Drugs
- Controlled Release
- Full Acquisition
- Payment Includes Cash for Equity
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com